Sacubitril/valsartan combines a neprilysin inhibitor with an angiotensin receptor blocker. As
an inhibitor of neprilysin, an enzyme that degrades biologically active natriuretic peptides …

Renin-angiotensin-aldosterone system (RAAS) inhibition is a mainstay of the
pharmacological treatment of heart failure with reduced ejection fraction (HFrEF). In the last …

Abstract Aims The PARADIGM-HF and PARAGON-HF trials tested sacubitril/valsartan
against active controls given renin–angiotensin system inhibitors (RASi) are ethically …

Current international guidelines recommend switching angiotensin converting enzyme
inhibitors (ACE-i) or angiotensin receptor blockers (ARBs) to sacubitril/valsartan (S/V) in …

Abstract Sacubitril/valsartan (LCZ696), a supramolecular sodium salt complex of the
neprilysin inhibitor prodrug sacubitril and the angiotensin receptor blocker (ARB) valsartan …

Abstract The Losartan Heart Failure Survival Study (ELITE II) and the Valsartan Heart Failure
Trial (Val-HeFT) both evaluated the efficacy and tolerability of a selective angiotensin II …

Purpose The objective of this meta-analysis is to determine how sacubitril/valsartan (SV)
compares to equivalent and sub-equivalent angiotensin receptor blockers (ARB) or …

With an estimated prevalence of 5.8 million in the USA and over 23 million people
worldwide, heart failure (HF) is growing in epidemic proportions. Despite the use of …

Recent studies have shown candesartan to be an effective therapy for heart failure (HF)
patients, producing a significant reduction in cardiovascular mortality and morbidity …

Angiotensin receptor blockers (ARBs) have a pharmacological role in the treatment of heart
failure through their blockade of the effects of angiotensin II. ARBs, however, lack the …